Nasdaq

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide.1 Rising cases has led to an uptick in new treatments moving through the clinical ...
Yahoo Finance

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of ...
Benzinga.com

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Monday, Alzamend Neuro Inc. (NASDAQ:ALZN) stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization. The company has partnered to ...
St. Louis American

Barnes-Jewish Hospital opens new Neuro-Critical Care Unit

Barnes-Jewish Hospital just opened its latest addition to its Neuro-Critical Care Unit, with new technologies and innovative patient care, on August 15. With a new total of 44 beds, Barnes-Jewish now ...